Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

718
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
718
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

588
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
588
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.1K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.1K
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.8K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.8K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.2K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.2K
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

406
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
406

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cultivating a resilient future workforce.

British dental journal·2025
Same author

Laser beam pointing stabilization using analog position-sensitive diodes.

The Review of scientific instruments·2025
Same author

Search for Quasiparticle Scattering in the Quark-Gluon Plasma with Jet Splittings in pp and Pb-Pb Collisions at sqrt[s_{NN}]=5.02  TeV.

Physical review letters·2025
Same author

First Measurement of A=4 Hypernuclei and Antihypernuclei at the LHC.

Physical review letters·2025
Same author

Probing Strangeness Hadronization with Event-by-Event Production of Multistrange Hadrons.

Physical review letters·2025
Same author

Estimating the Early Transmission Inhibition of New Treatment Regimens for Drug-Resistant Tuberculosis.

The Journal of infectious diseases·2025

Related Experiment Video

Updated: Mar 7, 2026

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

19.7K

TB Alliance regimen development for multidrug-resistant tuberculosis.

S Murray1, C Mendel1, M Spigelman1

  • 1The Global Alliance for TB Drug Development (TB Alliance), New York, New York, USA.

The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease
|February 28, 2017
PubMed
Summary

New tuberculosis (TB) drugs offer hope for improved treatment regimens. The TB Alliance is developing novel therapies for drug-susceptible, multidrug-resistant, and extensively drug-resistant TB through ongoing clinical trials.

More Related Videos

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.3K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.2K

Related Experiment Videos

Last Updated: Mar 7, 2026

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

19.7K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.3K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.2K

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Clinical Trials

Background:

  • The emergence of drug-resistant tuberculosis necessitates the development of novel therapeutic strategies.
  • Existing treatment regimens for tuberculosis (TB) have limitations in efficacy and duration.
  • The Global Alliance for TB Drug Development (TB Alliance) is a key player in advancing new anti-TB drug development.

Purpose of the Study:

  • To present an overview of the TB Alliance's pipeline for developing new tuberculosis treatment regimens.
  • To highlight novel regimens targeting drug-susceptible, multidrug-resistant (MDR-TB), and extensively drug-resistant (XDR-TB) tuberculosis.
  • To outline the rationale and goals of ongoing clinical trials for new TB therapies.

Main Methods:

  • Review of the TB Alliance's drug development pipeline.
  • Description of ongoing clinical trials including STAND, NC-005, Nix-TB, and LIN-CL001.
  • Presentation of the scientific rationale and objectives for each trial.

Main Results:

  • The TB Alliance pipeline includes novel regimens for various forms of TB.
  • Ongoing trials are evaluating the safety and efficacy of these new regimens.
  • Specific trial details and objectives are provided for STAND, NC-005, Nix-TB, and LIN-CL001.

Conclusions:

  • The TB Alliance is actively developing innovative treatment regimens to combat tuberculosis.
  • New drug approvals and ongoing clinical trials represent significant progress in TB treatment.
  • These efforts aim to provide more effective options for patients with all forms of TB, including resistant strains.